# OnCo record dpyd-genotyping (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/dpyd-genotyping/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "dpyd-genotyping" ;
  schema:name "DPYD genotyping and DPD phenotyping before fluoropyrimidines"@en ;
  schema:alternateName "DPYD testing"@en, "DPD deficiency testing"@en, "dihydropyrimidine dehydrogenase test"@en, "uracil phenotyping"@en, "DPYD*2A"@en ;
  schema:description "A one-off blood test done before fluorouracil or capecitabine that finds the roughly one in twenty-five people who break the drug down too slowly. Lowering their starting dose reduces severe and occasionally fatal toxicity, and in the one matched comparison published so far survival was not shortened overall."@en ;
  schema:url <https://onco.cc/technologies/dpyd-genotyping/> ;
  schema:dateModified "2026-10-20"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(18)30686-7>, <https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/>, <https://www.ema.europa.eu/en/news/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine>, <https://www.fda.gov/drugs/resources-information-approved-drugs/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine>, <https://doi.org/10.1200/JCO.22.02780>, <https://doi.org/10.1002/onco.13967> ;
  onco:status "standard-of-care" ;
  onco:tag "precision" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/anal/>, <https://onco.cc/cancers/oesophageal-adenocarcinoma/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/oncology-pharmacogenomics/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/ugt1a1-genotyping/>, <https://onco.cc/technologies/tpmt-nudt15-genotyping/> ;
  onco:drugs <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:institutions <https://onco.cc/institutions/ema/> ;
  onco:terms <https://onco.cc/terms/dose-modification/>, <https://onco.cc/terms/hand-foot-syndrome/>, <https://onco.cc/terms/mucositis/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/pharmacokinetics/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-henricks-lancet-oncol/> .